NEW YORK CITY -- Douglas A. Michels, president and CEO of OraSure Technologies, Inc., and Dr. Jack C. Chow, assistant director general for HIV/AIDS, TB and Malaria at the World Health Organization (WHO), presided over the market open ceremony today.
OraSure Technologies is the manufacturer of OraQuick® ADVANCE, the only U.S. FDA-approved rapid, HIV-1/2 test that can be used with oral fluid, whole blood and plasma and produce results in 20 minutes.
OraSure Technologies develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities.
OraSure Technologies is the leading supplier of oral-fluid collection devices and assays to the life insurance industry and public health markets for the detection of antibodies to HIV-1.
Source: OraSure
Uncovering a Hidden Risk: Alcohol Use Disorder Significantly Increases C difficile Infection Rates
April 10th 2025A groundbreaking study reveals a strong connection between alcohol use disorder and increased risk for Clostridioides difficile infection, challenging traditional assumptions and calling for enhanced infection prevention protocols.